Based on a research paper by Rifat Atun et al, RethinkHIV released a Policy Brief looking at the cost of Africa’s hidden debt and the impact of future treatment costs on countries’ growth. To meet the cost of lifetime treatment for AIDS/HIV would nearly double the debt-to GDP ratio for some countries in SSA.
RethinkHIV is a consortium of senior researchers from London School of Hygiene & Tropical Medicine, Imperial College London, Harvard School of Public Health, Centre for the Study of African Economies and Blavatnik School of Government at Oxford University.
The consortium will evaluate new evidence related to the costs, benefits, effects, fiscal implications, and developmental impacts of HIV interventions in sub-Saharan Africa, in order to maximise contributions to the fight against HIV there.
The aim of RethinkHIV is to find ways of creating, optimising, and sustaining fiscal space for domestic HIV investment, as well as exploring long-term, sustainable national and international financing mechanisms. RethinkHIV is funded by RUSH Foundation.